For example, a monoclonal antibody targeted to the scavenger receptor MARCO was shown to reprogram TAMs into M1-like macrophages, inducing anti-tumor activity (in models of breast cancer, colon carcinoma, and melanoma) and enhancing the efficacy of immune checkpoint therapy (75). This evidence concerns the gene MARCO and melanoma.